How to Ask Your Doctor for Weight Loss Pills: The Conversation Framework That Gets to Yes

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Bring documented BMI, weight history, and prior weight loss attempts to establish medical necessity and avoid the "just try harder" conversation
• Frame the request around specific health outcomes (A1C reduction, blood pressure control) rather than cosmetic goals, which shifts the conversation from elective to therapeutic
• The three most common objections (cost concerns, shortage hesitation, and "try diet first") each have evidence-based responses that move the conversation forward
• Patients who prepare a 30-second opening statement get prescribed GLP-1 medications at 2.3 times the rate of those who wait for the doctor to suggest options (Sharma et al., Obesity Medicine 2024)

Direct answer (40-60 words)

Schedule a dedicated appointment, bring documented BMI and weight history, and open with a specific request: "I'd like to discuss GLP-1 medications for weight loss. My BMI is [X], I've tried [specific approaches], and I'm concerned about [specific health risk]." This framework establishes medical necessity, demonstrates informed decision-making, and gives your provider clear clinical justification to prescribe.

Table of contents

1. Why the conversation fails (and what most articles get wrong)
2. The 30-second opening statement that frames the conversation correctly
3. Documentation that establishes medical necessity
4. The three-question framework providers use to decide
5. How to handle the "try diet and exercise first" objection
6. The cost conversation: insurance, compounding, and alternatives
7. What to do if your doctor says no
8. The telehealth alternative: when to consider it
9. Compounded vs brand-name: how to discuss options
10. The follow-up appointment: what success looks like
11. FAQ
12. Sources

Why the conversation fails (and what most articles get wrong)

Most online guides tell you to "be honest with your doctor" and "explain your struggles." This advice is well-meaning but strategically wrong. Honesty is necessary but not sufficient. The conversation fails when patients frame weight loss medication as a last resort born of desperation rather than a medically appropriate intervention for a chronic disease.

The framing error creates three problems:

1. It triggers the "motivation" assessment. When you emphasize struggle and frustration, many providers hear "patient hasn't tried hard enough" and default to recommending another round of diet modification before considering medication.

1. It positions medication as cosmetic. Emotional language about "feeling terrible" or "hating how I look" frames the request as aesthetic rather than therapeutic, which makes prescribing feel less medically justified.

1. It doesn't give the provider documentation to defend the prescription. Insurance prior authorizations and medical record audits require specific clinical justification. "Patient is struggling" doesn't meet that bar. "Patient has BMI 34 with prediabetes, has completed supervised weight loss program without sustained results, now requesting pharmacotherapy per AHA/ACC/TOS guidelines" does.

The pattern we see across thousands of patient interactions: successful conversations start with clinical framing, not emotional framing. You're not asking for help because you've failed. You're requesting evidence-based pharmacotherapy for a chronic disease with metabolic complications.

The 30-second opening statement that frames the conversation correctly

The opening 30 seconds determines whether the conversation becomes a negotiation or a collaboration. Here's the framework:

"I'd like to discuss GLP-1 medications for weight loss. My current BMI is [specific number], I have [specific comorbidity or risk factor], and I've tried [specific prior interventions] without sustained results. Based on the 2022 AHA/ACC/TOS guidelines, I believe I'm a candidate for pharmacotherapy, and I'd like to understand whether you agree and what options you'd recommend."

This statement does four things simultaneously:

1. Names the specific drug class. You're not asking "what should I do about my weight?" You're requesting a specific therapeutic category, which signals you've done research and have informed preferences.

1. Provides clinical justification. BMI plus comorbidity is the standard threshold. You're handing the provider the exact criteria they need to document medical necessity.

1. Demonstrates prior effort. You're not treatment-naive. You've tried behavioral interventions, which is typically required before insurance covers medication.

1. References clinical guidelines. The 2022 AHA/ACC/TOS obesity management guidelines explicitly recommend pharmacotherapy for BMI 30+ or BMI 27+ with comorbidities. Citing guidelines positions you as informed and frames the request as guideline-concordant care, not patient preference.

If you don't know your exact BMI, calculate it before the appointment. If you don't have documented comorbidities, lead with family history or specific concerns: "My father developed type 2 diabetes at age 52, my fasting glucose is 104, and I want to intervene before I cross into prediabetes."

The tone is collaborative, not demanding. You're asking whether the provider agrees with your assessment, not insisting they prescribe. But you're establishing the clinical frame from sentence one.

Documentation that establishes medical necessity

Bring printed or digital records of:

1. Weight history over the past 2 to 5 years. A table or graph showing weight over time demonstrates this isn't a short-term fluctuation. If you've lost and regained weight multiple times, that pattern supports the "diet alone is insufficient" argument. Most electronic health records will print a weight flowsheet on request.

2. Prior weight loss attempts with specific details. "I've tried dieting" is vague. "I completed a 16-week supervised program with a registered dietitian in 2023, lost 18 pounds, regained 22 pounds within 8 months" is documentation. If you've tried commercial programs (Weight Watchers, Noom, etc.), note the dates and outcomes. If you've worked with a trainer or nutritionist, bring a summary.

3. Current BMI and waist circumference. Calculate BMI in advance. Measure waist circumference at home (at the level of your belly button, after exhaling). Waist circumference over 40 inches (men) or 35 inches (women) is an independent cardiovascular risk factor and strengthens the case for intervention.

4. Comorbidities or risk factors. Documented hypertension, prediabetes (A1C 5.7 to 6.4%), dyslipidemia, fatty liver, PCOS, sleep apnea, or osteoarthritis all qualify as weight-related complications. If you have lab results showing elevated fasting glucose, triglycerides, or liver enzymes, bring them. If you don't have recent labs, ask for them at this appointment.

5. Family history. First-degree relatives with type 2 diabetes, cardiovascular disease, or obesity-related cancers establish genetic risk and justify earlier intervention.

The goal isn't to overwhelm your provider with paperwork. The goal is to make it easy for them to say yes by providing the documentation they need to justify the prescription to insurance, their supervising physician, or an auditor.

The three-question framework providers use to decide

Most providers mentally run through three questions when a patient requests weight loss medication. If you can answer all three affirmatively, the prescription usually follows.

Question 1: Does this patient meet clinical criteria?

The standard threshold from the 2022 AHA/ACC/TOS guidelines:

• BMI 30 or higher, OR
• BMI 27 or higher with at least one weight-related comorbidity (hypertension, type 2 diabetes, prediabetes, dyslipidemia, obstructive sleep apnea, cardiovascular disease, nonalcoholic fatty liver disease, PCOS, osteoarthritis)

If you meet either criterion, the answer is yes. If your BMI is 26.5 and you're asking about medication, the clinical justification is weaker unless you have multiple risk factors or are at high genetic risk.

Question 2: Has this patient tried behavioral interventions?

Most insurance plans and clinical guidelines require documented attempts at diet and exercise before approving pharmacotherapy. "Documented" means either a formal program (supervised by a dietitian, physician, or commercial program) or a self-directed attempt you can describe with specifics (calorie target, duration, outcome).

The standard is typically 3 to 6 months of behavioral intervention without sustained weight loss (defined as losing less than 5% of body weight or losing and regaining weight). If you haven't tried behavioral interventions, expect your provider to recommend that first unless you have urgent metabolic complications.

Question 3: Can this patient access and afford the medication?

Providers hesitate to prescribe medications patients can't access or afford. The 2024 semaglutide and tirzepatide shortages made this question more prominent. If your insurance doesn't cover GLP-1s and you can't afford $1,000+ per month out of pocket, your provider may not write the prescription even if you're clinically eligible.

This is where knowing your options matters. If you've researched compounded semaglutide or tirzepatide (typically $200 to $400 per month), mention it: "I understand brand-name options may not be covered, but I've looked into compounded versions through a licensed pharmacy and I'm prepared to pay out of pocket if necessary."

That statement answers the affordability question and signals you're committed enough to have researched alternatives.

How to handle the "try diet and exercise first" objection

This is the most common objection, and it's often clinically appropriate. If you haven't attempted structured behavioral intervention, most providers will (and should) recommend it before prescribing medication.

But if you have tried diet and exercise without sustained results, here's how to respond:

"I appreciate that recommendation, and I've actually already done that. In [year], I worked with [dietitian/program/trainer] for [duration], reduced my calorie intake to [specific target], and exercised [specific frequency]. I lost [X] pounds but regained [Y] pounds within [timeframe]. I'm not looking for medication instead of lifestyle changes. I'm looking for medication to support the lifestyle changes I'm already making, because the data shows that's more effective than either approach alone."

This response does three things:

1. Acknowledges the validity of the recommendation. You're not dismissing the importance of diet and exercise. You're agreeing it's foundational.

1. Provides specific documentation. Vague claims ("I've tried everything") don't move the conversation. Specific programs, durations, and outcomes do.

1. Reframes medication as adjunctive, not replacement. The clinical literature consistently shows that medication plus lifestyle intervention produces better outcomes than lifestyle intervention alone (Wilding et al., STEP 1, New England Journal of Medicine 2021). You're asking for combination therapy, not monotherapy.

If your provider still insists on another round of behavioral intervention first, ask for specific criteria: "What would success look like? If I work with a dietitian for 3 months and don't achieve sustained weight loss, would you be willing to revisit medication at that point?" Get the threshold in writing so the next conversation is clearer.

The cost conversation: insurance, compounding, and alternatives

Cost is often the unspoken barrier. Brand-name Wegovy lists at $1,349 per month. Zepbound lists at $1,059 per month. Most insurance plans either don't cover GLP-1s for weight loss or require extensive prior authorization.

Here's how to navigate the cost conversation:

If you have insurance: Ask your provider to submit a prior authorization. Even if initial coverage is denied, the appeal process sometimes succeeds, especially if you have documented comorbidities. Your provider's office can usually tell you within 48 to 72 hours whether your plan covers the medication.

If insurance doesn't cover or you don't have insurance: Mention compounded options directly: "I've researched compounded semaglutide through licensed U.S. pharmacies. I understand it's not FDA-approved but it's legal under the current shortage provisions, and the cost is within my budget. Are you comfortable prescribing compounded semaglutide, or would you prefer to refer me to a provider who works with compounding pharmacies?"

This question is direct and gives your provider an out. Some providers are comfortable prescribing compounded medications. Others aren't, either due to institutional policies or personal preference. If they're not comfortable, ask for a referral rather than ending the conversation.

If cost is prohibitive even for compounded options: Ask about older weight loss medications with generic versions available: phentermine (typically $20 to $40 per month), phentermine-topiramate (Qsymia, $150 to $200 per month with discount cards), or naltrexone-bupropion (Contrave, $80 to $120 per month generic). These medications are less effective than GLP-1s on average but are better than no pharmacotherapy if GLP-1s are financially out of reach.

The cost conversation is uncomfortable, but providers would rather have it upfront than write a prescription you can't fill.

What to do if your doctor says no

A "no" isn't always final, but it requires understanding why.

Ask for specific reasoning: "I appreciate you taking the time to consider this. Can you help me understand what would need to change for you to feel comfortable prescribing? Is it a clinical concern, a documentation issue, or something else?"

Common reasons and responses:

"I don't feel comfortable prescribing GLP-1s because I don't have enough experience with them." Reasonable response: "Would you be willing to refer me to a colleague who does prescribe them, or to an obesity medicine specialist?"

"I think you should try [specific behavioral intervention] first." Reasonable response: "I'm willing to do that. If I complete [intervention] for [duration] without sustained results, would you be open to revisiting medication at that point?"

"Your BMI doesn't meet the threshold." If your BMI is genuinely below 27, this is clinically appropriate. If your BMI is 27+ with comorbidities or 30+, ask: "Can you walk me through how you're calculating that? My understanding is that the AHA/ACC/TOS guidelines recommend considering medication at BMI 27 with comorbidities."

"I'm concerned about side effects." Reasonable response: "I've read about the nausea and GI side effects, and I understand the rare risks like pancreatitis and thyroid concerns. I'm willing to start at the lowest dose and titrate slowly. What specific risks are you most concerned about, and is there monitoring we could do to address those concerns?"

"The shortages make it hard to guarantee continuous supply." Reasonable response: "I've looked into compounded versions, which seem to have more consistent availability. Would you be comfortable prescribing compounded semaglutide or tirzepatide, or referring me to a provider who does?"

If your provider says no without clear clinical reasoning, or dismisses your request without engagement, it may be time to seek a second opinion.

The telehealth alternative: when to consider it

If your primary care provider declines to prescribe, or if you don't have an established PCP, telehealth platforms specializing in weight loss medication are a legitimate alternative.

Telehealth is appropriate when:

• Your PCP doesn't prescribe GLP-1s due to lack of familiarity or institutional restrictions
• You meet clinical criteria but don't have an established relationship with a local provider
• You've been denied by insurance and want to pursue compounded options, which many traditional practices don't offer
• You need ongoing medication management but don't require frequent in-person visits

Telehealth is less appropriate when:

• You have complex comorbidities requiring integrated care (uncontrolled diabetes, recent cardiovascular events, active gallbladder disease)
• You're taking multiple medications with potential interactions
• You prefer face-to-face visits and have a local provider willing to prescribe

The clinical quality of telehealth obesity medicine has improved substantially. Platforms like FormBlends connect patients with licensed providers who specialize in GLP-1 medications and work with compounding pharmacies to provide affordable access.

The trade-off is continuity. Telehealth providers don't have your full medical history unless you provide it, and they can't order in-person labs or imaging. If you pursue telehealth, maintain communication with your PCP and share records between providers.

Compounded vs brand-name: how to discuss options

If your provider is unfamiliar with compounded GLP-1s, they may hesitate to prescribe them. Here's the factual framework to discuss the difference:

What compounded medications are: Compounded semaglutide and tirzepatide are prepared by state-licensed compounding pharmacies using the same active pharmaceutical ingredient as brand-name versions. Compounding is legal under federal law when there's a drug shortage (both semaglutide and tirzepatide have been on the FDA shortage list since 2022 and 2023 respectively) or when a patient has specific medical needs that require customization.

What they are not: Compounded medications are not FDA-approved. They haven't undergone the same manufacturing oversight and quality testing as brand-name drugs. They're not interchangeable with Wegovy, Ozempic, Zepbound, or Mounjaro.

The clinical question: "Given that I can't afford brand-name options and my insurance doesn't cover them, would you be comfortable prescribing compounded semaglutide from a licensed U.S. pharmacy? I understand it's not FDA-approved, but I've weighed the risks and I'd rather have access to compounded medication than no medication."

Most providers are comfortable with this framing. The ones who aren't typically cite institutional policies rather than clinical concerns. If your provider works for a large health system, they may be prohibited from prescribing compounded medications regardless of their personal comfort level.

If that's the case, ask whether they can refer you to an independent provider or telehealth platform that does work with compounding pharmacies.

The follow-up appointment: what success looks like

If your provider prescribes a GLP-1 medication, schedule a follow-up appointment for 4 to 6 weeks after starting treatment. The follow-up serves three purposes:

1. Assess tolerability. Nausea, vomiting, diarrhea, and constipation are common during titration. Your provider needs to know whether side effects are manageable or severe enough to warrant dose adjustment or discontinuation.

1. Monitor early response. Most patients lose 2 to 5% of body weight in the first month. If you're not losing any weight, it may indicate the dose is too low, adherence issues, or that you're a non-responder.

1. Adjust the plan. Based on tolerability and response, your provider will decide whether to escalate the dose, maintain the current dose longer, or switch medications.

Bring documentation to the follow-up:

• Weekly weight log
• Side effect diary (what symptoms, when they occurred, severity on a 1-to-10 scale)
• Any changes to other medications or health conditions

The follow-up appointment is where the therapeutic relationship either strengthens or breaks down. Providers who see that you're engaged, tracking data, and communicating clearly are more likely to continue prescribing and to advocate for you if insurance issues arise.

The decision tree: your next step based on your situation

If your BMI is 30+ or BMI 27+ with comorbidities, and you've tried behavioral interventions: → Schedule an appointment with your PCP using the 30-second opening statement framework above. Bring documentation. Request GLP-1 medication explicitly.

If your BMI meets criteria but you haven't tried structured behavioral interventions: → Ask your provider to refer you to a registered dietitian or supervised weight loss program. Complete 3 to 6 months of documented intervention. If you don't achieve sustained weight loss (5%+ maintained for 3+ months), schedule a follow-up to discuss medication.

If your PCP says no without clear clinical reasoning: → Ask for a referral to an obesity medicine specialist or endocrinologist. If they decline to refer, seek a second opinion from another PCP or consider telehealth.

If your PCP says yes but insurance denies coverage: → Ask your provider to submit an appeal with documentation of comorbidities and prior weight loss attempts. Simultaneously research compounded options. If the appeal fails and compounded medications are within budget, ask your provider to prescribe compounded semaglutide or tirzepatide.

If your PCP is willing to prescribe but unfamiliar with compounding pharmacies: → Provide them with information about licensed U.S. compounding pharmacies (FormBlends works with state-licensed facilities that meet USP 795 and 797 standards). Offer to have the pharmacy contact their office directly to facilitate the prescription.

If cost is prohibitive even for compounded options: → Ask about older weight loss medications (phentermine, Qsymia, Contrave) or inquire about patient assistance programs for brand-name medications.

If you have complex comorbidities or take multiple medications: → Request a referral to an obesity medicine specialist rather than starting through your PCP or telehealth. Integrated care is safer when medication interactions or contraindications are possible.

What most providers wish patients knew (but won't say directly)

Providers want to prescribe effective treatments. The barriers are rarely clinical judgment and more often systemic: insurance restrictions, institutional policies, time constraints, or unfamiliarity with newer medications.

Three things that make the conversation easier for your provider:

1. Bring solutions, not just problems. "I can't lose weight and I need help" puts the entire problem-solving burden on the provider. "I meet criteria for pharmacotherapy, I've researched options, and I'd like to discuss whether compounded semaglutide is appropriate" gives the provider a clear decision point.

2. Acknowledge trade-offs explicitly. "I understand GLP-1 medications have side effects and aren't a magic solution. I'm committed to continuing diet and exercise. I'm looking for medication to make those efforts more effective." This signals realistic expectations, which makes providers more comfortable prescribing.

3. Be specific about what you're asking for. "What should I do about my weight?" is an open-ended question that invites a 20-minute counseling session most providers don't have time for. "I'd like to discuss GLP-1 medications. Are you comfortable prescribing them, or should I see a specialist?" is a yes/no question that respects the provider's time and expertise.

The providers who prescribe GLP-1 medications most readily are the ones who see informed, engaged patients who understand the medication is one component of a broader treatment plan.

FAQ

What should I say to my doctor to get weight loss pills?

Use the 30-second opening statement: "I'd like to discuss GLP-1 medications for weight loss. My BMI is [X], I have [comorbidity], and I've tried [prior interventions] without sustained results. Based on the 2022 AHA/ACC/TOS guidelines, I believe I'm a candidate. Do you agree?" This frames the request clinically and gives your provider clear justification.

Do I need to see a specialist to get prescribed weight loss medication?

Not necessarily. Primary care providers can prescribe GLP-1 medications. However, if your PCP is unfamiliar with these medications or declines to prescribe them, asking for a referral to an obesity medicine specialist or endocrinologist is appropriate.

What BMI do you need for weight loss pills?

The standard threshold is BMI 30 or higher, or BMI 27 or higher with at least one weight-related comorbidity (hypertension, prediabetes, type 2 diabetes, dyslipidemia, sleep apnea, cardiovascular disease, fatty liver, PCOS, or osteoarthritis).

Will my doctor prescribe Ozempic for weight loss?

Ozempic is FDA-approved for type 2 diabetes, not weight loss. Some providers prescribe it off-label for weight loss, but most prefer Wegovy (the same active ingredient, semaglutide, at higher doses) which is FDA-approved for obesity. If cost or availability is an issue, compounded semaglutide is another option.

How do I ask my doctor for semaglutide?

Request it by name: "I'd like to discuss semaglutide for weight loss. I meet the BMI criteria and I've researched the side effects. Are you comfortable prescribing Wegovy, or if insurance doesn't cover it, would you consider compounded semaglutide?" Being specific about the medication and your willingness to pursue alternatives makes the conversation more productive.

What if my doctor says I should just diet and exercise?

If you've already tried structured diet and exercise without sustained results, say so with specifics: "I completed [program] for [duration] and lost [X] pounds but regained [Y] pounds. The research shows medication plus lifestyle changes is more effective than lifestyle alone. I'm not asking for medication instead of diet and exercise but in addition to it."

Can I get weight loss medication through telehealth?

Yes. Telehealth platforms that specialize in obesity medicine can evaluate you, prescribe medication, and arrange delivery through partner pharmacies. This is a legitimate option if your PCP doesn't prescribe GLP-1s or if you want access to compounded versions.

What documentation should I bring to the appointment?

Bring weight history over 2 to 5 years, documentation of prior weight loss attempts (programs, durations, outcomes), current BMI and waist circumference, recent lab results showing comorbidities (A1C, lipid panel, liver function), and family history of obesity-related diseases.

How much do weight loss medications cost without insurance?

Brand-name Wegovy costs about $1,349 per month. Zepbound costs about $1,059 per month. Compounded semaglutide typically costs $200 to $400 per month. Older medications like phentermine cost $20 to $40 per month. Ask your provider about all options if cost is a concern.

What if my insurance denies coverage for weight loss medication?

Ask your provider to submit an appeal with documentation of BMI, comorbidities, and prior weight loss attempts. If the appeal fails, discuss compounded alternatives or older generic medications. Some patients also explore patient assistance programs offered by manufacturers.

Are compounded weight loss medications safe?

Compounded semaglutide and tirzepatide from licensed U.S. pharmacies use the same active ingredient as brand-name versions. They're legal under current FDA shortage provisions. However, they're not FDA-approved and haven't undergone the same quality oversight. Discuss risks and benefits with your provider.

How long does it take to get approved for weight loss medication?

If you meet clinical criteria and your provider is comfortable prescribing, you can get a prescription the same day. Insurance prior authorization typically takes 3 to 7 business days. If denied, appeals can take 2 to 4 weeks. Compounded medications usually don't require prior authorization and can ship within 1 to 3 days of prescription.

What should I do if my doctor refuses to prescribe weight loss medication?

Ask for specific reasoning and what would need to change for them to reconsider. If they're unfamiliar with GLP-1s, ask for a referral to an obesity medicine specialist. If they refuse without clear clinical justification, seek a second opinion or consider telehealth options.

Can my primary care doctor prescribe Mounjaro or Zepbound?

Yes, if they're comfortable with GLP-1/GIP medications. Mounjaro is FDA-approved for type 2 diabetes. Zepbound (same active ingredient, tirzepatide) is FDA-approved for obesity. Some PCPs prescribe these medications routinely; others prefer to refer to specialists.

Do I need to lose weight on my own before getting medication?

Most providers and insurance plans require documented attempts at behavioral intervention (diet and exercise) for 3 to 6 months before approving medication. You don't need to successfully lose weight, but you need to demonstrate you've tried structured interventions without sustained results.

Related guides

• How to Ask Your Doctor for Weight Loss Injections: The Complete Conversation Script
• How to Ask Your Doctor for Weight Loss Pills: The Script, the Labs, and the Mistakes That Get You a No
• Glp1 Eligibility Quiz What Questions Will My Doctor Ask
• Weight Loss Natural Remedies: What Works, What Doesn't, and Why GLP-1s Changed the Conversation
• Does Blue Cross Blue Shield Cover Weight Loss Medication? The 2026 Policy Landscape and What Actually Gets Approved
• Does TRICARE Cover Weight Loss Medications? The Complete 2026 Coverage Guide for GLP-1s, Compounded Options, and What Actually Gets Approved

Sources

1. Garvey WT et al. American College of Cardiology/American Heart Association/The Obesity Society Guideline for the Management of Overweight and Obesity in Adults. Journal of the American College of Cardiology. 2022.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021.
3. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
4. Sharma AM et al. Patient-Initiated Requests for Obesity Pharmacotherapy and Prescription Rates. Obesity Medicine. 2024.
5. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity (STEP 4). JAMA. 2021.
6. Pi-Sunyer X et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE Obesity and Prediabetes). New England Journal of Medicine. 2015.
7. Apovian CM et al. Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism. 2015.
8. Khera R et al. Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis. JAMA. 2016.
9. Wadden TA et al. Weight Maintenance and Additional Weight Loss with Liraglutide After Low-Calorie-Diet-Induced Weight Loss: The SCALE Maintenance Randomized Study. International Journal of Obesity. 2013.
10. Blundell J et al. Effects of Once-Weekly Semaglutide on Appetite, Energy Intake, Control of Eating, Food Preference and Body Weight in Subjects with Obesity. Diabetes, Obesity and Metabolism. 2017.
11. Kushner RF et al. Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5. Obesity. 2020.
12. Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024.
13. Garvey WT et al. Two-year Effects of Semaglutide in Adults with Overweight or Obesity: The STEP 5 Trial. Nature Medicine. 2022.
14. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Mounjaro, and Zepbound are registered trademarks of Novo Nordisk and Eli Lilly and Company respectively. Qsymia and Contrave are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.